In:
European Journal of Clinical Investigation, Wiley, Vol. 44, No. 8 ( 2014-08), p. 743-752
Abstract:
The determination of rivaroxaban and apixaban from serum samples of patients may be beneficial in specific clinical situations when additional blood sampling for plasma and thus the determination of factor Xa activity is not feasible or results are not plausible. Materials and methods The primary aim of this study was to compare the concentrations of rivaroxaban and apixaban in serum with those measured in plasma. Secondary aims were the performance of three different chromogenic methods and concentrations in patients on treatment with rivaroxaban 10 mg od ( n = 124) or 20 mg od ( n = 94) or apixaban 5 mg bid ( n = 52) measured at different time. Results Concentrations of rivaroxaban and apixaban in serum were about 20–25% higher compared with plasma samples with a high correlation ( r = 0·79775–0·94662) using all assays (all P 〈 0·0001). The intraclass correlation coefficients were about 0·90 for rivaroxaban and 0·55 for apixaban. Mean rivaroxaban concentrations were higher at 2 and 3 h compared with 1 and 12 h after administration measured from plasma and serum samples (all P ‐values 〈 0·05) and were not different between 1 vs. 12 h (plasma and serum). Conclusions The results indicate that rivaroxaban and apixaban concentrations can be determined specifically from serum samples.
Type of Medium:
Online Resource
ISSN:
0014-2972
,
1365-2362
DOI:
10.1111/eci.2014.44.issue-8
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
2004971-7
